Press Releases

Press Releases

September 7, 2022
CytomX Therapeutics Presents Overview of Conditionally-Activated Antibody-Drug Conjugate (ADC) Programs Including Next Generation EpCAM-Targeting CX-2051
- Presentation at World ADC Conference in San Diego - - CX-2051 integrates CytomX core platform expertise to potentially maximize therapeutic window - SOUTH SAN FRANCISCO, Calif. , Sept. 07, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally
Additional Formats
July 13, 2022
CytomX Therapeutics Provides Strategic Update
- Company to focus internal efforts on wholly-owned next-generation conditionally activated therapeutics, including IFN alpha-2b cytokine and EpCAM-directed ADC, INDs planned for 2023 - - Partnered clinical-stage programs continue to advance: Phase 2 programs, BMS-986249 (anti-CTLA-4) and CX-2029
Additional Formats
June 16, 2022
CytomX Therapeutics Announces New Employment Inducement Grants
SOUTH SAN FRANCISCO, Calif. , June 16, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that on June 15, 2022 , the Company granted two new employees options to purchase a total of 109,000
Additional Formats
Displaying 1 - 10 of 23